The fourth Drug Discovery Re-Invented Meeting brings together experts in medicinal chemistry, structure-based drug design, computational chemistry, emerging drug targets, and novel technology platforms. The meeting is extremely interactive with enthusiastic question and answer sessions following each talk. This meeting remains unique with respect to the breadth of participants and focus on new approaches to discovering drugs. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical "open innovation" models. Key Sessions New Approaches in Biotech, Academia, and Pharma New Screening Technologies and Drug Targets Structure, Modeling, and Fragment-based Design Government and Non-profit Sector in Drug Discovery and Development Importance of CROs in Supporting the Virtual Drug Discovery Model Emerging Pharmacological Targets Industry Exhibit Scientific chairs: Bill Kinney (Enterin Inc.) and Charles Reynolds (GFree Bio, LLC)